Editas Medicine, Inc. 8-K

What Happened Editas Medicine, Inc. (EDIT) filed an 8-K on June 18, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders elected two Class I directors — Bernadette Connaughton and Elliott Levy, M.D. — each to serve until the 2029 annual meeting. Shareholders also approved, on an advisory basis, the compensation for named executive officers (say-on-pay) and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Bernadette Connaughton elected as Class I director: 28,660,181 votes For; 10,789,549 Votes Withheld; 26,404,190 broker non-votes.
• Elliott Levy, M.D. elected as Class I director: 37,095,058 votes For; 2,354,672 Votes Withheld; 26,404,190 broker non-votes.
• Advisory vote on executive compensation (say-on-pay): 32,914,258 Votes For; 6,322,885 Votes Against; 212,587 Abstaining; 26,404,190 broker non-votes.
• Ratification of auditor (PricewaterhouseCoopers LLP) for FY2026: 64,686,839 Votes For; 774,471 Votes Against; 392,610 Abstaining; 0 broker non-votes.

Why It Matters These certified vote tallies confirm the company’s board composition for the next term and show shareholder support for management pay and the company’s choice of auditor. The large number of broker non-votes on some items indicates many shares were held by brokers who did not vote on non-routine matters, which can affect the voting outcome thresholds for contested or advisory proposals. The filing is a formal disclosure required under the Securities Exchange Act and provides investors with the official results to assess governance and oversight at Editas.